| pubmed-article:7846948 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7846948 | lifeskim:mentions | umls-concept:C0012253 | lld:lifeskim |
| pubmed-article:7846948 | lifeskim:mentions | umls-concept:C0004238 | lld:lifeskim |
| pubmed-article:7846948 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:7846948 | pubmed:dateCreated | 1995-3-9 | lld:pubmed |
| pubmed-article:7846948 | pubmed:abstractText | The role of cardiac glycosides for conversion of atrial fibrillation to simus rhythm is controversially discussed. In a prospective study, 45 patients with paroxysmal atrial fibrillation were randomly assigned to one of three treatment groups (of 15 patients each). Group I received oral digoxin, three times 0.125 mg up to twice 0.25 mg daily; group II oral digoxin twice 0.125 mg and quinidine hydrogen sulphate 750-1000 mg daily; group III oral digoxin three times 0.125 mg and flecaimide 200-300 mg daily. During a mean observation period of 11 months, digoxin alone was significantly less effective (p < 0.05) in reducing or suppressing paroxyms of atrial fibrillation than digoxin plus quinidine or flecainide. The use of digoxin remains a mainstay of treatment for rate control in atrial fibrillation. To convert atrial fibrillation to sinus rhythm, however, the addition of a type I or III antiarrhythmic agent is necessary. | lld:pubmed |
| pubmed-article:7846948 | pubmed:language | ger | lld:pubmed |
| pubmed-article:7846948 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7846948 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7846948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7846948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7846948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7846948 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7846948 | pubmed:issn | 0300-5860 | lld:pubmed |
| pubmed-article:7846948 | pubmed:author | pubmed-author:SteinbeckGG | lld:pubmed |
| pubmed-article:7846948 | pubmed:author | pubmed-author:HaberlRR | lld:pubmed |
| pubmed-article:7846948 | pubmed:author | pubmed-author:KnezAA | lld:pubmed |
| pubmed-article:7846948 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7846948 | pubmed:volume | 83 Suppl 5 | lld:pubmed |
| pubmed-article:7846948 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7846948 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7846948 | pubmed:pagination | 71-3 | lld:pubmed |
| pubmed-article:7846948 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:meshHeading | pubmed-meshheading:7846948-... | lld:pubmed |
| pubmed-article:7846948 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7846948 | pubmed:articleTitle | [The use of digitalis glycosides in atrial fibrillation]. | lld:pubmed |
| pubmed-article:7846948 | pubmed:affiliation | Medizinische Klinik I, Universität München, Klinikum Grosshadern. | lld:pubmed |
| pubmed-article:7846948 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7846948 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7846948 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7846948 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:7846948 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
